Bridgeway Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q2	$267K	Buy	66,700 +25,400	+62%	+$102K	0.01%	894
2025 Q1	$131K	Hold	41,300	–	–	﹤0.01%	994
2024 Q4	$221K	Sell	41,300 -86,000	-68%	-$460K	﹤0.01%	984
2024 Q3	$672K	Hold	127,300	–	–	0.01%	783
2024 Q2	$232K	Sell	127,300 -97,000	-43%	-$177K	0.01%	1023
2024 Q1	$399K	Buy	224,300 +75,000	+50%	+$134K	0.01%	982
2023 Q4	$263K	Hold	149,300	–	–	0.01%	1081
2023 Q3	$218K	Buy	149,300 +40,000	+37%	+$58.4K	0.01%	1083
2023 Q2	$250K	Sell	109,300 -50,000	-31%	-$115K	0.01%	1084
2023 Q1	$145K	Hold	159,300	–	–	﹤0.01%	1167
2022 Q4	$135K	Hold	159,300	–	–	﹤0.01%	1169
2022 Q3	$130K	Hold	159,300	–	–	﹤0.01%	1224
2022 Q2	$158K	Hold	159,300	–	–	﹤0.01%	1140
2022 Q1	$261K	Sell	159,300 -65,000	-29%	-$106K	0.01%	1119
2021 Q4	$541K	Buy	224,300 +65,000	+41%	+$157K	0.01%	960
2021 Q3	$771K	Sell	159,300 -50,000	-24%	-$242K	0.01%	906
2021 Q2	$559K	Buy	209,300 +5,000	+2%	+$13.4K	0.01%	1035
2021 Q1	$629K	Buy	204,300 +70,600	+53%	+$217K	0.01%	1032
2020 Q4	$476K	Hold	133,700	–	–	0.01%	965
2020 Q3	$536K	Hold	133,700	–	–	0.01%	861
2020 Q2	$364K	Hold	133,700	–	–	0.01%	967
2020 Q1	$282K	Hold	133,700	–	–	0.01%	949
2019 Q4	$727K	Buy	+133,700	New	+$727K	0.01%	826
2019 Q2	–	Sell	-89,000	Closed	-$358K	–	1336
2019 Q1	$358K	Buy	89,000 +9,400	+12%	+$37.8K	﹤0.01%	1118
2018 Q4	$292K	Sell	79,600 -25,000	-24%	-$91.7K	﹤0.01%	1132
2018 Q3	$897K	Buy	104,600 +19,600	+23%	+$168K	0.01%	927
2018 Q2	$933K	Hold	85,000	–	–	0.01%	898
2018 Q1	$980K	Hold	85,000	–	–	0.01%	849
2017 Q4	$881K	Hold	85,000	–	–	0.01%	886
2017 Q3	$1.36M	Buy	+85,000	New	+$1.36M	0.02%	734